Bristol-Myers Squibb Company (NYSE:BMY), which focuses on innovative cancer and immunology treatments, is a leader in the ...

For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Discover the top 10 high-yield stocks for June 2025! Learn how to boost income with dividend growth, strong financials, and ...

We recently published a list of Jim Cramer Recently Discussed These 15 Stocks. In this article, we are going to take a look ...

Moderna was recently told that the Health and Human Services Department (HHS) had withdrawn a $766million grant awarded by ...

Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7 ...

Under terms of the deal, Bristol Myers will pay $1.5 billion upfront, and a total of $2 billion in anniversary payments for the next few years to co-develop and co-sell BioNTech's BNT327 for the ...

Arvinas noted that vepdegestrant, which is being developed alongside Pfizer to treat certain types of advanced or metastatic breast cancer, was generally well tolerated in the clinical trial, and that ...

The latest readout from the BREAKWATER study showed "unprecedented" median overall survival of 30.3 months for ...

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...